Zhihong Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhihong Fang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Bing Xu
Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China
7 shared publications Haijun Zhao
Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, PR China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, PR China
4 shared publicationsManman Deng
Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, PR China; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, PR China
4 shared publicationsYuanfei Shi
Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China
4 shared publicationsLian Yu
Department of Hematology and Rheumatology, Longyan First Hospital, Affiliated to Fujian Medical University, Longyan, People’s Republic of China
3 shared publicationsGenhong Li
Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1726461
Clinical characteristics and prognostic factors of Clostridium perfringens infection complicated by massive intravascular hemolysis in patients with hematologic diseases: a retrospective case series study
Clostridium perfringens (CP), an anaerobic Gram-positive bacterium, is commonly associated with food poisoning and gas gangrene. In rare instances, it can cause fatal massive intravascular hemolysis (MIH), a condition associated with exceedingly high mortality that poses a serious clinical challenge. A retrospective analysis was performed using a fatal case of T-lymphoblastic lymphoma/leukemia complicated by CP-associated acute hemolysis treated at our center in November 2024 and case reports of CP-associated MIH in hematologic patients from January 1987 to September 2025. A total of 23 eligible cases from our institution and published literature were included. The cohort consisted of 60.8% ( n = 14) male patients, with a mean age of 45.87 ± 17.94 years. All patients presented with fever, hematuria was observed in 69.5% of patients, shock in 78.2%, and altered mental status (AMS) in 60.8%. The overall mortality rate was 73.9%, with a median survival time of 13.5 (6, 24) hours among non-survivors. AMS was identified as an independent risk factor for mortality (OR = 14.03, 95% CI: 1.19–165.08, p = 0.036). The pathogenic cascade, conceptualized as a “double-hit” model, is triggered by the synergistic action of α-toxin and θ-toxin. Together, they induce fulminant intravascular hemolysis and a systemic inflammatory response, culminating in organ injury. Although no specific therapeutics are available, immediate empirical combination antibiotic therapy (such as penicillin with clindamycin) is paramount. Adjunctive measures, including intensive care support and toxin removal strategies, are essential components of care. This study emphasizes the severity of CP-MIH in hematologic patients and identifies AMS as a key prognostic marker, underscoring the need for early intervention and further research into rapid diagnostics and targeted treatments.
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1726461
Open AccessClinical characteristics and prognostic factors of Clostridium perfringens infection complicated by massive intravascular hemolysis in patients with hematologic diseases: a retrospective case series study
Clostridium perfringens (CP), an anaerobic Gram-positive bacterium, is commonly associated with food poisoning and gas gangrene. In rare instances, it can cause fatal massive intravascular hemolysis (MIH), a condition associated with exceedingly high mortality that poses a serious clinical challenge. A retrospective analysis was performed using a fatal case of T-lymphoblastic lymphoma/leukemia complicated by CP-associated acute hemolysis treated at our center in November 2024 and case reports of CP-associated MIH in hematologic patients from January 1987 to September 2025. A total of 23 eligible cases from our institution and published literature were included. The cohort consisted of 60.8% ( n = 14) male patients, with a mean age of 45.87 ± 17.94 years. All patients presented with fever, hematuria was observed in 69.5% of patients, shock in 78.2%, and altered mental status (AMS) in 60.8%. The overall mortality rate was 73.9%, with a median survival time of 13.5 (6, 24) hours among non-survivors. AMS was identified as an independent risk factor for mortality (OR = 14.03, 95% CI: 1.19–165.08, p = 0.036). The pathogenic cascade, conceptualized as a “double-hit” model, is triggered by the synergistic action of α-toxin and θ-toxin. Together, they induce fulminant intravascular hemolysis and a systemic inflammatory response, culminating in organ injury. Although no specific therapeutics are available, immediate empirical combination antibiotic therapy (such as penicillin with clindamycin) is paramount. Adjunctive measures, including intensive care support and toxin removal strategies, are essential components of care. This study emphasizes the severity of CP-MIH in hematologic patients and identifies AMS as a key prognostic marker, underscoring the need for early intervention and further research into rapid diagnostics and targeted treatments.
- Open Access
- 2 May 2024
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (9) , 3004-3008
CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia
- 2 May 2024
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (9) , 3004-3008
Open AccessCD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia
- Open Access
- 17 October 2023
- Published by Springer Nature in Drugs in R&D
- Vol. 23 (4) , 439-451
Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways
Background The FLT3/ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this study, we attempted to evaluate the antitumor activity of simvastatin, a member of the statin class of drugs, in vitro and in vivo models of FLT3/ITD AML and to identify the potential mechanisms. Methods Cell Counting Kit-8 (CCK-8) and Annexin V/propidium iodide (PI) staining kits were used to detect cell viability and apoptosis, respectively. Subsequently, Western blot and rescue experiment were applied to explore the potential molecular mechanism. In vivo anti-leukemia activity of simvastatin was evaluated in xenograft mouse models. Results In vitro experiments revealed that simvastatin inhibited AML progression in a dose- and time-dependent manner, while in vivo experiments showed that simvastatin significantly reduced tumor burden in FLT3/ITD xenograft mouse models. After simvastatin treatment of FLT3/ITD AML cells, intracellular Rap1 was downregulated and the phosphorylation levels of its downstream targets MEK, ERK and p38 were significantly inhibited. The rescue experiment showed that mevalonate, an intermediate product of the metabolic pathway of mevalonate, and its downstream geranylgeranyl pyrophosphate (GGPP) played a key role in this process. Finally, we demonstrate that simvastatin can induce apoptosis of primary AML cells, while having no effect on peripheral blood mononuclear cells from normal donors. Conclusions Simvastatin can selectively and effectively eradicate FLT3/ITD AML cells in vitro and in vivo, and its mechanism may be related to the disruption of the HMG-CoA reductase pathway and the downregulation of the MEK/ERK and p38-MAPK signaling pathways.
- 17 October 2023
- Published by Springer Nature in Drugs in R&D
- Vol. 23 (4) , 439-451
Open AccessSimvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways
Background The FLT3/ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this study, we attempted to evaluate the antitumor activity of simvastatin, a member of the statin class of drugs, in vitro and in vivo models of FLT3/ITD AML and to identify the potential mechanisms. Methods Cell Counting Kit-8 (CCK-8) and Annexin V/propidium iodide (PI) staining kits were used to detect cell viability and apoptosis, respectively. Subsequently, Western blot and rescue experiment were applied to explore the potential molecular mechanism. In vivo anti-leukemia activity of simvastatin was evaluated in xenograft mouse models. Results In vitro experiments revealed that simvastatin inhibited AML progression in a dose- and time-dependent manner, while in vivo experiments showed that simvastatin significantly reduced tumor burden in FLT3/ITD xenograft mouse models. After simvastatin treatment of FLT3/ITD AML cells, intracellular Rap1 was downregulated and the phosphorylation levels of its downstream targets MEK, ERK and p38 were significantly inhibited. The rescue experiment showed that mevalonate, an intermediate product of the metabolic pathway of mevalonate, and its downstream geranylgeranyl pyrophosphate (GGPP) played a key role in this process. Finally, we demonstrate that simvastatin can induce apoptosis of primary AML cells, while having no effect on peripheral blood mononuclear cells from normal donors. Conclusions Simvastatin can selectively and effectively eradicate FLT3/ITD AML cells in vitro and in vivo, and its mechanism may be related to the disruption of the HMG-CoA reductase pathway and the downregulation of the MEK/ERK and p38-MAPK signaling pathways.
- Open Access
- 14 November 2022
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (18) , 7760-7774
m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease
Rationale: Bone destruction is a hallmark of multiple myeloma (MM) and affects more than 80% of patients. Although previous works revealed the roles of N6-methyladenosine (m6A) reader hnRNPA2B1 in the development of tumors, whether hnRNPA2B1 regulates bone destruction in MM is still unknown.
- 14 November 2022
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (18) , 7760-7774
Open Accessm6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease
Rationale: Bone destruction is a hallmark of multiple myeloma (MM) and affects more than 80% of patients. Although previous works revealed the roles of N6-methyladenosine (m6A) reader hnRNPA2B1 in the development of tumors, whether hnRNPA2B1 regulates bone destruction in MM is still unknown.
- Open Access
- 10 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
High-grade B-cell lymphoma with concurrent MYC and BCL2 rearrangements (HGBL-DHL) is a rare, aggressive mature B-cell malignancy with a high likelihood of treatment failure following front-line immunochemotherapies. Patients with HGBL-DHL who develop a relapsed or refractory disease have little effective therapeutic strategies and show very poor clinical outcomes, thus calling for development of novel therapies for this specific patient population. In this study, we investigated the preclinical anti-lymphoma efficacies and potential mechanism of action of a novel treatment approach, combining the BCL2 inhibitor venetoclax with CS2164, a new orally active multitarget inhibitor, in HGBL-DHL models. This combination therapy exhibited a robust synergistic cytotoxicity against HGBL-DHL cells, evidenced by cooperatively inducing loss of cell viability and promoting cell apoptosis. Moreover, coadministration of CS2164 and venetoclax resulted in significant superior suppression of HGBL-DHL cell growth and remarkably abrogated tumor burden in a HGBL-DHL-xenografted mouse model. The synergistic lethality of CS2164 and venetoclax in HGBL-DHL cells was associated with induction of DNA damage and impairment of DNA repair ability. Of importance, the combined treatment almost abolished the expression of both BCL2 and MYC, two hallmark proteins of HGBL-DHL, and substantially blunted the activity of PI3K/AKT/mTOR signaling cascade. In addition, MCL1 and BCL-XL, two well-characterized contributors for venetoclax resistance, were significantly lessened in the presence of CS2164 and venetoclax, thus leading to the accumulation of proapoptotic proteins BAX and PUMA and then initiating the intrinsic apoptosis pathway. Taken together, these findings suggest that the regimen of CS2164 and venetoclax is highly effective to eliminate HGBL-DHL cells in the preclinical setting, warranting further clinical investigations of this regimen for the treatment of unfavorable HGBL-DHL patients.
- 10 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessCS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
High-grade B-cell lymphoma with concurrent MYC and BCL2 rearrangements (HGBL-DHL) is a rare, aggressive mature B-cell malignancy with a high likelihood of treatment failure following front-line immunochemotherapies. Patients with HGBL-DHL who develop a relapsed or refractory disease have little effective therapeutic strategies and show very poor clinical outcomes, thus calling for development of novel therapies for this specific patient population. In this study, we investigated the preclinical anti-lymphoma efficacies and potential mechanism of action of a novel treatment approach, combining the BCL2 inhibitor venetoclax with CS2164, a new orally active multitarget inhibitor, in HGBL-DHL models. This combination therapy exhibited a robust synergistic cytotoxicity against HGBL-DHL cells, evidenced by cooperatively inducing loss of cell viability and promoting cell apoptosis. Moreover, coadministration of CS2164 and venetoclax resulted in significant superior suppression of HGBL-DHL cell growth and remarkably abrogated tumor burden in a HGBL-DHL-xenografted mouse model. The synergistic lethality of CS2164 and venetoclax in HGBL-DHL cells was associated with induction of DNA damage and impairment of DNA repair ability. Of importance, the combined treatment almost abolished the expression of both BCL2 and MYC, two hallmark proteins of HGBL-DHL, and substantially blunted the activity of PI3K/AKT/mTOR signaling cascade. In addition, MCL1 and BCL-XL, two well-characterized contributors for venetoclax resistance, were significantly lessened in the presence of CS2164 and venetoclax, thus leading to the accumulation of proapoptotic proteins BAX and PUMA and then initiating the intrinsic apoptosis pathway. Taken together, these findings suggest that the regimen of CS2164 and venetoclax is highly effective to eliminate HGBL-DHL cells in the preclinical setting, warranting further clinical investigations of this regimen for the treatment of unfavorable HGBL-DHL patients.
- Open Access
- 22 July 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (7) , 1-11
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
Bcl-2 inhibitors display an effective activity in acute myeloid leukemia (AML), but its clinical efficacy as a monotherapy was limited in part owing to failure to target other antiapoptotic Bcl-2 family proteins, such as Mcl-1. In this context, the combination strategy may be a promising approach to overcome this barrier. Here, we report the preclinical efficacy of a novel strategy combining ABT-199 with triptolide (TPL), a natural product extracted from a traditional Chinese medicine, in AML. Combination treatment exhibited markedly increased cytotoxicity in leukemic cells irrespective of p53 status while largely sparing normal cells of the hematopoietic lineage. Moreover, co-administration of ABT-199 with TPL dramatically suppressed leukemia progression as well as prolonged animal survival in a xenograft AML model. The potentiated effect of ABT-199 and TPL against AML was associated with activation of the mitochondrum-related intrinsic apoptotic pathway through a mechanism reciprocally modulating Bcl-2 family proteins. In this case, TPL not only downregulated Mcl-1 but also upregulated proapoptotic BH3-only proteins, thereby overcoming the resistance toward ABT-199. Conversely, ABT-199 abrogated Bcl-2-mediated cytoprotection against TPL. Together, these findings suggest that the regimen combining TPL and ABT-199 might be active against AML by inducing robust apoptosis through reciprocal regulation of anti- and proapoptotic Bcl-2 family proteins, therefore providing a strong rationale for the clinical investigation of this combination regimen for the treatment of AML.
- 22 July 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (7) , 1-11
Open AccessCombining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
Bcl-2 inhibitors display an effective activity in acute myeloid leukemia (AML), but its clinical efficacy as a monotherapy was limited in part owing to failure to target other antiapoptotic Bcl-2 family proteins, such as Mcl-1. In this context, the combination strategy may be a promising approach to overcome this barrier. Here, we report the preclinical efficacy of a novel strategy combining ABT-199 with triptolide (TPL), a natural product extracted from a traditional Chinese medicine, in AML. Combination treatment exhibited markedly increased cytotoxicity in leukemic cells irrespective of p53 status while largely sparing normal cells of the hematopoietic lineage. Moreover, co-administration of ABT-199 with TPL dramatically suppressed leukemia progression as well as prolonged animal survival in a xenograft AML model. The potentiated effect of ABT-199 and TPL against AML was associated with activation of the mitochondrum-related intrinsic apoptotic pathway through a mechanism reciprocally modulating Bcl-2 family proteins. In this case, TPL not only downregulated Mcl-1 but also upregulated proapoptotic BH3-only proteins, thereby overcoming the resistance toward ABT-199. Conversely, ABT-199 abrogated Bcl-2-mediated cytoprotection against TPL. Together, these findings suggest that the regimen combining TPL and ABT-199 might be active against AML by inducing robust apoptosis through reciprocal regulation of anti- and proapoptotic Bcl-2 family proteins, therefore providing a strong rationale for the clinical investigation of this combination regimen for the treatment of AML.
- 1 May 2020
- Published by Elsevier in Experimental Cell Research
- Vol. 390 (1) , 111934
Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis
- 1 May 2020
- Published by Elsevier in Experimental Cell Research
- Vol. 390 (1) , 111934
Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis
- 1 July 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 855, 252-261
Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage
- 1 July 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 855, 252-261
Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage
- 1 June 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 853, 193-200
CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models
- 1 June 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 853, 193-200
CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models
- 1 August 2018
- Published by Elsevier in Experimental Cell Research
- Vol. 369 (2) , 356-362
CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo
- 1 August 2018
- Published by Elsevier in Experimental Cell Research
- Vol. 369 (2) , 356-362
CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo